HCV

Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle
Philippe Roingeard, Julie Dreneau, Jean-Christophe Meunier

Gut May 2017, 66 (5) 759-761; DOI: 10.1136/gutjnl-2016-312774
HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
Jannick Prentoe, Lieven Verhoye, Rodrigo Velázquez Moctezuma, Caroline Buysschaert, Ali Farhoudi, Richard Wang, Harvey Alter, Philip Meuleman, Jens Bukh

Gut Dec 2016, 65 (12) 1988-1997; DOI: 10.1136/gutjnl-2015-310300
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice
Koen Vercauteren, Richard J P Brown, Ahmed Atef Mesalam, Juliane Doerrbecker, Sabin Bhuju, Robert Geffers, Naomi Van Den Eede, C Patrick McClure, Fulvia Troise, Lieven Verhoye, Thomas Baumert, Ali Farhoudi, Riccardo Cortese, Jonathan K Ball, Geert Leroux-Roels, Thomas Pietschmann, Alfredo Nicosia, Philip Meuleman

Gut Dec 2016, 65 (12) 2029-2034; DOI: 10.1136/gutjnl-2014-309045
Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
Nguyen Dinh Van, Christine S Falk, Lisa Sandmann, Florian W R Vondran, Fabian Helfritz, Heiner Wedemeyer, Michael P Manns, Sandra Ciesek, Thomas von Hahn

Gut Jun 2016, 65 (6) 1015-1023; DOI: 10.1136/gutjnl-2014-308003
The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
Annette von Delft, Isla S Humphreys, Anthony Brown, Katja Pfafferott, Michaela Lucas, Paul Klenerman, Georg M Lauer, Andrea L Cox, Silvana Gaudieri, Eleanor Barnes

Gut Jan 2016, 65 (1) 112-123; DOI: 10.1136/gutjnl-2014-308724
Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?
Hamish Innes, David Goldberg, John Dillon, Sharon J Hutchinson

Gut Nov 2015, 64 (11) 1800-1809; DOI: 10.1136/gutjnl-2014-308166
IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells
Charline Miot, Elodie Beaumont, Dorothée Duluc, Hélène Le Guillou-Guillemette, Laurence Preisser, Erwan Garo, Simon Blanchard, Isabelle Hubert Fouchard, Christophe Créminon, Patricia Lamourette, Isabelle Fremaux, Paul Calès, Françoise Lunel-Fabiani, Jérôme Boursier, Oliver Braum, Helmut Fickenscher, Philippe Roingeard, Yves Delneste, Pascale Jeannin

Gut Sep 2015, 64 (9) 1466-1475; DOI: 10.1136/gutjnl-2013-306604
Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C
Ramón San Miguel, Vicente Gimeno-Ballester, Antonio Blázquez, Javier Mar

Gut Aug 2015, 64 (8) 1277-1288; DOI: 10.1136/gutjnl-2014-307772
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C
Alessio Aghemo, Raffaele De Francesco

Gut Jun 2015, 64 (6) 860-862; DOI: 10.1136/gutjnl-2014-307958
Viral entry inhibition: too late for hepatitis C, but promising for other viral infections
Jean-Michel Pawlotsky

Gut Mar 2015, 64 (3) 362-364; DOI: 10.1136/gutjnl-2014-307452

Main menu

HCV

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

HCV

Pages